27 completed, 11 recruiting, 8 unknown, 6 not yet recruiting. 56 Phase 1, 23 Phase 2.
Follow Pharmaceutical Preparations: new trials by email Literature Review of Pharmaceutical Preparations trials Research Report on Pharmaceutical Preparations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SIMBA in Irritable Bowel Syndrome (IBS) Rifaximin (drug), fluid biopsy capsule - Irritable Bowel Syndrome (IBS), Microbiome | Phase 1 | Not yet recruiting | University of Calgary | 180 | 2026-11-01 | 2026-10-20 |
| The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. Psilocybin (drug), Placebo - Healthy Participants, Placebo - Control | Phase 1 | Not yet recruiting | Gabriella Gobbi | 50 | 2026-09-01 | 2026-02-25 |
| Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema Octreotide (drug), Placebo - Diabetic Macular Edema | Phase 1 | Withdrawn | University of Alabama at Birmingham | 2026-08-31 | 2026-10-13 | |
| A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors VMD-102 - Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | VM Discovery, Inc. | 111 | 2026-07-16 | 2026-11-03 |
| Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | David Bartlett, MD | 10 | 2026-06-03 | 2026-08-04 |
| A Study of Psychedelics in Healthy Older Adults With Low Well-being Psilocybin (drug), Dextromethorphan (DXM) - Anhedonia in Healthy Volunteers, Older Adults (50-90 Years) | Phase 1 | Recruiting | Jennifer Mitchell | 80 | 2026-06-01 | 2026-09-09 |
| Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) Tirzepatide, Placebo, [11C]raclopride plus drug - Alcohol Use Disorder (AUD) | Phase 1 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 176 | 2026-05-20 | 2026-10-13 |
| Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2) - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 10 | 2026-05-01 | 2026-04-07 |
| A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle., Spironolactone (drug) - Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | Starlight Therapeutics Inc. | 68 | 2026-05-01 | 2026-03-30 |
| Combining Latency Reversing Agents to Address the HIV Reservoir Pyrimethamine (PYR), Lenalidomide, Topiramate (drug) - HIV (Human Immunodeficiency Virus), HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Erasmus Medical Center | 30 | 2026-04-01 | 2026-02-03 |
| To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer JPI-547, Irinotecan (drug) - Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Onconic Therapeutics Inc. | 49 | 2026-02-27 | 2026-01-23 |
| RCT of Psilocybin-assisted CBT for Depression Psilocybin (drug), cognitive behavioral therapy, Minimal supportive therapy - Major Depressive Diorder | Phase 1 / Phase 2 | Recruiting | University of California, Los Angeles | 50 | 2026-01-05 | 2026-02-12 |
| The Effect of Local Infiltration of Tranexamic Acid on Postoperative Blood Loss in Orthognathic Surgery Tranexamic Acid, Normal Saline Solution (NSS), Lidocaine (drug) - Postoperative Blood Loss in Patient Undergoing Orthognathic Surgery | Phase 1 / Phase 2 | Not yet recruiting | Ramathibodi Hospital | 25 | 2025-05-12 | 2025-05-21 |
| A Multi-Arm, Platform Trial For Relapsed Neuroblastoma Bevacizumab, Dinutuximab beta, Irinotecan (drug) - Relapsed Neuroblastoma | Phase 1 / Phase 2 | Recruiting | University of Birmingham | 160 | 2024-11-11 | 2026-01-12 |
| Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024 Group 1 drug, Group 2: Drug and placebo, Group 3: Drug and palcebo - Ocular Surface Symptom, Ocular Surface Disease | Phase 1 | Unknown | Mohsen Pourazizi | 150 | 2024-10-30 | 2024-10-03 |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Paxalisib, Opdualag, Irinotecan (drug) - Childhood Cancer, Childhood Solid Tumor | Phase 1 / Phase 2 | Recruiting | Australian & New Zealand Children's Haematology/Oncology Group | 90 | 2024-07-10 | 2026-01-28 |
| Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case Clomiphene Citrate and letrozole - Polycystic Ovarian Syndrome | Phase 1 | Completed | HITEC-Institute of Medical Sciences | 42 | 2024-06-07 | 2026-05-07 |
| Opioid Free Anesthesia in Shoulder Arthroscope fentanyl, Lidocaine (drug) - Measure Time to First Rescue Analgesia Following Extubation | Phase 1 | Completed | Ain Shams University | 60 | 2024-03-12 | 2025-02-19 |
| A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte) - Musculoskeletal Injury | Phase 1 / Phase 2 | Recruiting | Cellcolabs Clinical LTD. | 30 | 2023-10-20 | 2024-04-19 |
| R-2487 in Patients With Rheumatoid Arthritis R-2487 DP - Arthritis, Rheumatoid | Phase 1 | Recruiting | Rise Therapeutics LLC | 73 | 2023-10-19 | 2026-06-12 |
Showing 20 of 56. Sign in to see all of them.
Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Lymphoma (3) · Neoplasm Metastasis (3) · Recurrence (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Mesothelioma, Malignant (2) · Pleural Effusion, Malignant (2) · Polycystic Ovary Syndrome (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Acquired Immunodeficiency Syndrome (1) · Alcoholism (1) · Anemia, Sickle Cell (1) · Anxiety Disorders (1) · Arteriosclerosis (1)
Regional Hospital Holstebro (4) · GlaxoSmithKline (2) · MEI Pharma, Inc. (2) · University Hospital, Clermont-Ferrand (2) · Ain Shams University (1) · Aljazeera Hospital (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Australian & New Zealand Children's Haematology/Oncology Group (1) · Beijing 302 Hospital (1) · Beni-Suef University (1) · Catabasis Pharmaceuticals (1) · Cellcolabs Clinical LTD. (1) · City of Hope Medical Center (1) · Daiichi Sankyo Co., Ltd. (1) · David Bartlett, MD (1)
United States (23) · Australia (3) · China (3) · Egypt (3) · France (3) · Belgium (2) · Canada (2) · Germany (2) · South Korea (2) · United Kingdom (2) · Austria (1) · Iran (1) · Japan (1) · Netherlands (1) · New Zealand (1)
Erling B Pedersen, Professor (4) · Jesper N Bech, MD, Ph.D. (2) · Jesper N Bech, MD, Ph.d. (2) · Robert D Mass, MD (2) · Barry J Byrne, MD, PhD (1) · Bruno Scheller, MD (1) · Casper Rokx, MD PhD (1) · Cesar Serrano, MD (1) · Charles S. Grob, MD (1) · Christopher N Andrews, MD MSc (1) · Daniel Morgenstern, Dr (1) · David Bartlett, MD (1) · David C Whitcomb, MD, PhD (1)
PMID 15583741, PMID 15890495, PMID 15978266, PMID 16816065, PMID 17101615, PMID 18536865, PMID 20819978, PMID 22440499, PMID 22794786, PMID 23154216, PMID 23570273, PMID 25552401, PMID 26229445, PMID 30908574, PMID 37160401, PMID 37327461, PMID 38502995, PMID 38652877, PMID 39356039
2017 (1), P01HL059412 (1), R34AT013077 (1)